| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8902b26da143e3ca1c4eeb1a8843690 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16234 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate |
2014-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efa6dbdfdc198452599b2f1dacdd7158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a20090ddbb9e23fede063cb8aaa4692d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_640ec40e7da6e78d7b4443e9e8b8d7a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57ae81b25744f758c936603d375c22b6 |
| publicationDate |
2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10047137-B2 |
| titleOfInvention |
Antibodies against novel PD1 isoforms and uses thereof |
| abstract |
The present invention pertains to antibodies against a novel isoform of human PD1 protein (Δ42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against Δ42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against Δ42PD1 are monoclonal. |
| priorityDate |
2013-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |